[Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
The serum level of tumor marker CA-125 was determined by a specific immunoradiometric assay in 45 healthy persons (control group), in patients with benign ovarian tumors (13), patients with ovarian carcinoma in remission (15) and progression (28), patients with non-ovarian carcinoma (39), patients with benign peritoneal processes (6), and patients with malignant (3) or inflammatory (10) hepatic diseases. A follow-up study was carried out for a few months (4-11) in some patients after the primary therapy for ovarian cancer. The serum levels of CA-125 were always below the border value (30 U/ml) in healthy persons, in patients with benign ovarian tumors (without peritoneal affection), in patients with ovarian cancer in remission, patients with extraovarian cancers without metastases or with extraperitoneal metastases, and in patients with acute viral hepatitis. Patients with the progression of ovarian carcinoma and patients with peritoneal affection (malignant or benign) had elevated CA-125 values. The findings were in a good correlation with the clinical course in the follow-up study.